Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies

Paolo Verdecchia, Gilles Dagenais, Jeff Healey, Peggy Gao, Antonio L. Dans, Irina Chazova, Azan S. Binbrek, Gianluca Iacobellis, Rafael Ferreira, Nicolaas Holwerda, Nicholas Karatzas, Matyas Keltai, Giuseppe Mancia, Peter Sleight, Koon Teo, Salim Yusuf

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Evidence on new-onset atrial fibrillation in high-risk vascular patients without heart failure is limited. New-onset atrial fibrillation was a prespecified secondary objective of the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) studies. Methods: We studied 30 424 ONTARGET/TRANSCEND patients (mean age ± SD, 66.4 ± 7.0) with vascular disease or complicated diabetes who were in sinus rhythm at entry. A copy of ECG was sent to central office every time new atrial fibrillation was detected by investigators. Results: During a median follow-up period of 4.7 years, new atrial fibrillation occurred in 2092 patients (15.1 per 1000 patient-years). Risk of atrial fibrillation increased with age, SBP and pulse pressure, left ventricular hypertrophy, BMI, serum creatinine and history of hypertension, coronary artery disease and cerebrovascular disease (all P < 0.01). After adjustment for BMI and other variables, atrial fibrillation risk increased with hip circumference. History of hypertension was associated with a 34% higher risk of new atrial fibrillation. New atrial fibrillation portended an increased risk of congestive heart failure [hazard ratio 2.89, 95% confidence interval (CI) 2.45-3.40, P < 0.01] and cardiovascular death (hazard ratio 1.22, 95% CI 1.05-1.41, P < 0.01). Risk of stroke was unaffected (hazard ratio 1.14, 95% CI 0.93-1.40), whereas that of myocardial infarction was reduced (hazard ratio 0.64, 95% CI 0.50-0.82). Patients with new atrial fibrillation were more likely to receive vitamin K antagonists (P < 0.01), statins (P < 0.05) and β-blockers (P < 0.01) than those in sinus rhythm. Conclusion: New atrial fibrillation is common in high-risk vascular patients and is associated with several risk factors including history of hypertension. Hip circumference was the strongest anthropometric predictor. Despite extensive use of modern therapies, new atrial fibrillation carries a high risk of congestive heart failure and death over a relatively short term.

Original languageEnglish
Pages (from-to)1004-1014
Number of pages11
JournalJournal of Hypertension
Volume30
Issue number5
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Ramipril
Atrial Fibrillation
Cardiovascular Diseases
Blood Pressure
Confidence Intervals
Heart Failure
Hypertension
Blood Vessels
Hip
telmisartan
Cerebrovascular Disorders
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Vitamin K
Left Ventricular Hypertrophy
Vascular Diseases
Coronary Artery Disease
Creatinine
Electrocardiography

Keywords

  • angiotensin receptor blockers
  • angiotensin-converting enzyme inhibitors
  • atrial fibrillation
  • hypertension
  • left ventricular hypertrophy
  • obesity
  • ramipril
  • telmisartan

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. / Verdecchia, Paolo; Dagenais, Gilles; Healey, Jeff; Gao, Peggy; Dans, Antonio L.; Chazova, Irina; Binbrek, Azan S.; Iacobellis, Gianluca; Ferreira, Rafael; Holwerda, Nicolaas; Karatzas, Nicholas; Keltai, Matyas; Mancia, Giuseppe; Sleight, Peter; Teo, Koon; Yusuf, Salim.

In: Journal of Hypertension, Vol. 30, No. 5, 01.05.2012, p. 1004-1014.

Research output: Contribution to journalArticle

Verdecchia, Paolo ; Dagenais, Gilles ; Healey, Jeff ; Gao, Peggy ; Dans, Antonio L. ; Chazova, Irina ; Binbrek, Azan S. ; Iacobellis, Gianluca ; Ferreira, Rafael ; Holwerda, Nicolaas ; Karatzas, Nicholas ; Keltai, Matyas ; Mancia, Giuseppe ; Sleight, Peter ; Teo, Koon ; Yusuf, Salim. / Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. In: Journal of Hypertension. 2012 ; Vol. 30, No. 5. pp. 1004-1014.
@article{74ae42bc0ee345328b16450ea295ad08,
title = "Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies",
abstract = "Lippincott Williams & Wilkins.",
keywords = "angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, atrial fibrillation, hypertension, left ventricular hypertrophy, obesity, ramipril, telmisartan",
author = "Paolo Verdecchia and Gilles Dagenais and Jeff Healey and Peggy Gao and Dans, {Antonio L.} and Irina Chazova and Binbrek, {Azan S.} and Gianluca Iacobellis and Rafael Ferreira and Nicolaas Holwerda and Nicholas Karatzas and Matyas Keltai and Giuseppe Mancia and Peter Sleight and Koon Teo and Salim Yusuf",
year = "2012",
month = "5",
day = "1",
doi = "10.1097/HJH.0b013e3283522a51",
language = "English",
volume = "30",
pages = "1004--1014",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies

AU - Verdecchia, Paolo

AU - Dagenais, Gilles

AU - Healey, Jeff

AU - Gao, Peggy

AU - Dans, Antonio L.

AU - Chazova, Irina

AU - Binbrek, Azan S.

AU - Iacobellis, Gianluca

AU - Ferreira, Rafael

AU - Holwerda, Nicolaas

AU - Karatzas, Nicholas

AU - Keltai, Matyas

AU - Mancia, Giuseppe

AU - Sleight, Peter

AU - Teo, Koon

AU - Yusuf, Salim

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - angiotensin receptor blockers

KW - angiotensin-converting enzyme inhibitors

KW - atrial fibrillation

KW - hypertension

KW - left ventricular hypertrophy

KW - obesity

KW - ramipril

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=84859885041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859885041&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e3283522a51

DO - 10.1097/HJH.0b013e3283522a51

M3 - Article

C2 - 22495138

AN - SCOPUS:84859885041

VL - 30

SP - 1004

EP - 1014

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 5

ER -